

CLAIMS:

1. An antibody or fragment thereof which induces apoptosis in cells expressing Her2.

5

2. The antibody of Claim 1 which recognizes an epitope on a Her2 polypeptide which is recognized by the monoclonal antibody produced by the hybridoma cell line ATCC No. _____

10

3. The antibody of Claim 1 which is a monoclonal antibody.

4. The antibody of Claim 1 which is a humanized antibody.

15

5. The antibody of Claim 1 which is a human antibody.

20

6. A hybridoma cell line capable of producing the antibody of Claim 3.

7. The antibody of Claim 1 wherein the fragment is a F(ab) or Fab' fragment.

25

8. An antibody produced by the hybridoma cell line ATCC No. _____ .

9. Hybridoma cell line ATCC No. _____ .

30

10. The antibody of Claim 1 wherein the Her2 expressing cells are tumor cells.

11. The tumor cells of Claim 10 which are derived from breast, ovarian, prostate, gastric and colorectal cancers.

35

12. A method for inducing apoptosis in Her2 expressing cells comprising administering an amount of the antibody of Claim 1 sufficient to induce apoptosis.

5

13. The method of Claim 12 wherein the cells are cancer cells.

14. A method of treating cancer in a patient comprising administering an amount of an antibody of Claim 1 sufficient to induce apoptosis.

10

15. A pharmaceutical composition comprising an amount of an antibody of Claim 1 sufficient to induce apoptosis in a mixture with a pharmaceutically acceptable adjuvant.

15

16. The composition of Claim 15 wherein the antibody is a monoclonal antibody.

20

17. The composition of Claim 15 wherein the antibody is a humanized antibody.

18. The composition of Claim 15 wherein the antibody is a human antibody.

25